Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.

Xiao Y, Zhang S, Dai N, Fei G, Goh KL, Chun HJ, Sheu BS, Chong CF, Funao N, Zhou W, Chen M.

Gut. 2019 Aug 13. pii: gutjnl-2019-318365. doi: 10.1136/gutjnl-2019-318365. [Epub ahead of print]

2.

Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.

Kawai T, Oda K, Funao N, Nishimura A, Matsumoto Y, Mizokami Y, Ashida K, Sugano K.

Gut. 2018 Jun;67(6):1033-1041. doi: 10.1136/gutjnl-2017-314852. Epub 2017 Dec 1.

3.

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.

Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T, Ashida K, Sugano K.

Gut. 2018 Jun;67(6):1042-1051. doi: 10.1136/gutjnl-2017-314010. Epub 2017 Oct 7.

4.

Reply to the letter by Dr Graham concerning ethical and interpretation issues with vonoprazan-containing H. pylori eradication therapy.

Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M.

Gut. 2017 Feb;66(2):386. doi: 10.1136/gutjnl-2016-312011. Epub 2016 May 3. No abstract available.

PMID:
27196601
5.

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.

Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M.

Gut. 2016 Sep;65(9):1439-46. doi: 10.1136/gutjnl-2015-311304. Epub 2016 Mar 2.

6.

SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.

Inagaki N, Onouchi H, Sano H, Funao N, Kuroda S, Kaku K.

Lancet Diabetes Endocrinol. 2014 Feb;2(2):125-32. doi: 10.1016/S2213-8587(13)70149-9. Epub 2013 Nov 1.

PMID:
24622716

Supplemental Content

Support Center